2:47 PM
Jan 09, 2018
 |  BC Extra  |  Company News

Spark to develop gene therapy for Pompe's

Spark Therapeutics Inc. (NASDAQ:ONCE) said it is developing a preclinical gene therapy for Pompe's disease using its liver-targeting adeno-associated virus (AAV) platform. The therapy, SPK-GAA, will use a novel acid alpha glucosidase (GAA) transgene in-licensed last year from Genethon (Evry, France). Spark unveiled the program on Monday at the J.P. Morgan Healthcare Conference in San Francisco.

The company said...

Read the full 274 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >